Reweighed Charlson comorbidity index more accurate in men with prostate cancer

August 1, 2011

A reweighed Charlson comorbidity index (CCI) based on prostate cancer-specific data and long-term follow-up predicts long-term, other-cause mortality in prostate cancer patients better than the original CCI.

Key Points

Washington-A reweighed Charlson comorbidity index (CCI) based on prostate cancer-specific data and long-term follow-up predicts long-term, other-cause mortality in prostate cancer patients better than the original CCI, according to UCLA researchers.

Based on its performance, the revised CCI may be useful for counseling men about management of early-stage prostate cancer, said first author Timothy Daskivich, MD, a urology resident at UCLA's David Geffen School of Medicine working with Mark S. Litwin, MD, MPH, and colleagues.